Abstract:
The accurate diagnosis of small-cell lung cancer (SCLC) is crucial, as treatment strategies differ from those of other lung cancers. This systematic review aims to identify proteins differentially expressed in SCLC compared to normal lung tissue, evaluating their potential utility in diagnosing and prognosing the disease. Additionally, the study identifies proteins differentially expressed between SCLC and large cell neuroendocrine carcinoma (LCNEC), aiming to discover biomarkers distinguishing between these two subtypes of neuroendocrine lung cancers. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a comprehensive search was conducted across PubMed/MEDLINE, Scopus, Embase, and Web of Science databases. Studies reporting proteomics information and confirming SCLC and/or LCNEC through histopathological and/or cytopathological examination were included, while review articles, non-original articles, and studies based on animal samples or cell lines were excluded. The initial search yielded 1705 articles, and after deduplication and screening, 16 articles were deemed eligible. These studies revealed 117 unique proteins significantly differentially expressed in SCLC compared to normal lung tissue, along with 37 unique proteins differentially expressed between SCLC and LCNEC. In conclusion, this review highlights the potential of proteomics technology in identifying novel biomarkers for diagnosing SCLC, predicting its prognosis, and distinguishing it from LCNEC.
摘要:
小细胞肺癌(SCLC)的准确诊断至关重要,因为治疗策略不同于其他肺癌。本系统综述旨在鉴定SCLC与正常肺组织相比差异表达的蛋白质。评估它们在诊断和预测疾病方面的潜在效用。此外,该研究鉴定了SCLC和大细胞神经内分泌癌(LCNEC)之间差异表达的蛋白质,旨在发现区分这两种神经内分泌肺癌亚型的生物标志物。遵循系统审查和荟萃分析(PRISMA)指南的首选报告项目,在PubMed/MEDLINE进行了全面搜索,Scopus,Embase,和WebofScience数据库。包括报告蛋白质组学信息并通过组织病理学和/或细胞病理学检查确认SCLC和/或LCNEC的研究。在评论文章时,非原创文章,排除基于动物样本或细胞系的研究。最初的搜索产生了1705篇文章,在重复数据删除和筛选之后,16篇文章被认为是合格的。这些研究表明,与正常肺组织相比,SCLC中117种独特的蛋白质显着差异表达,以及37种独特的蛋白质在SCLC和LCNEC之间差异表达。总之,这篇综述强调了蛋白质组学技术在鉴定诊断SCLC的新型生物标志物方面的潜力,预测其预后,并将其与LCNEC区分开来。